GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC), today announced that the U.S. Patent and Trademark Office has granted Patent No. 7,214,368 entitled, “Therapeutic Regimen For Treating Cancer Comprising the Administration Of Adenoviral Vectors Comprising A TNF-a Transgene,” and U.S. Patent No. 7,195,896, entitled, “Deficient Adenoviral Vector and Plasmid with Adenoviral Component.” The first patent specifically covers the method of using TNFerade™ in combination with radiation, to treat solid tumors or soft tissue sarcoma, further strengthening the Company’s broad intellectual property position around its lead product candidate. The second patent broadens coverage of the methods used to produce GenVec’s adenovectors in its 293-ORF6 cell line, including TNFerade, which further enhances the value of the Company’s proprietary core adenovector technology platform.
